Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Abcam

Biotech & Life Sciences · Cambridge, United Kingdom · Founded 1998 · IPO 2005 Unicorn

Life science protein research tools and reagents

Valuation
$5.30B
Market cap · 2026
Revenue
$477M
Latest reported FY
EBITDA
$56M
Latest reported FY

Investors

1 investor on Abcam's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 1 investor entered at this stage
University of Cambridge

Global footprint

Where Abcam has talent and traffic

AI talent share
0.7% of workforce is AI talent
(13 of 1,885 staff)
Core AI30.16%
Other AI100.53%
Non-AI workforce1,87299.31%
Workforce by country
30 countries with
team presence
🇬🇧 United Kingdom48%
🇺🇸 United States28.4%
🇨🇳 China10%
🇮🇳 India2.7%
🇸🇬 Singapore2.4%
Top 5 of 30 shown
Web traffic by country
670K monthly visits
across markets
🇺🇸 United States28.7%
🇬🇧 United Kingdom10.6%
🏳️ Korea6%
🏳️ Republic of3.5%
🇨🇳 China3.4%
Top 5 markets shown

Patent intelligence

$49M patent portfolio · 31 active families

Estimated portfolio value
$49M
0.92% of market cap · 16× smaller than top peer BioNTech ($780M)
31 active patent families
Where Abcam innovates Molecular biologyCell biologyAntiendomysial antibodiesBiochemistrySite-specific recombination

Where Abcam concentrates vs peers

Each axis is a top-10 topic across Abcam and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Abcam's 8 investments and acquisitions.

Every disclosed deal where Abcam appeared as a backer or acquirer, 2011–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

8 deals across Abcam's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Abcam deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Abcam's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        8 of 8 deals

        Market sentiment

        What the market is saying about Abcam

        An AI-synthesized read of the highest-engagement posts about Abcam on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Abcam on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.